TG and neoplasm: Previous studies showed some clinicopathological features (e.g., sex, tumor size, lymphovascular invasion, number of metastatic lymph nodes [LNs], ratio of metastatic to examined LNs [LNR], extranodal extension, and preablative-stimulated thyroglobulin [Ps-Tg]) may affect the response to therapy (5–11).